Loading…
← CockpitCompetitor Analysis › 300725.SZ PharmaBlock Sciences (Nanjing), Inc. Class AOpen in the cockpit ↗

PharmaBlock Sciences (Nanjing), Inc. Class A300725.SZCompetitor analysis, valuation and peers

China · CNY·Industrials›Miscellaneous Commercial Services

Chinese CRO/CDMO supplying fine chemical building blocks and custom synthesis for drug discovery.

≈ A China-based pharma building-blocks CDMOMomentum strong 64
Mkt cap
$1.36B
US dollars, full cap
Free float
85%
of shares outstanding
$/day
$134M
20-day average traded
Fwd P/E
37.5×
forward earnings
ROIC−WACC
-3.6 pp
WACC 11.7%
Hurdle
+10 pp
Req g minus delivered
Next earnings
161 days
28 Apr 2027
Close · CNYCN¥40.06
1D-5.6%
1W-14.6%
1M-11.9%
3M-26.9%
6M+5.4%
YTD+3.9%
1Y-3.3%
ATR %7.0%
52w lowhigh30.4% off high

What PharmaBlock Sciences (Nanjing) does

Chinese CRO/CDMO supplying fine chemical building blocks and custom synthesis for drug discovery.

Sells a catalog of many small-molecule building blocks in small quantities to drug-discovery labs, then follows promising ones into larger custom-made quantities as drugs advance through trials, giving it work from discovery through to commercial supply. Overseas customers account for the bulk of sales.

In one line: A China-based pharma building-blocks CDMO.

Products and services

  • Building-block chemicals
  • Custom synthesis/CDMO services

Customers

  • Global pharma/biotech R&D customers

Where it sits in the supply chain

  • Biopharma services
  • Fine chemicals/building blocks
  • Custom synthesis, CDMO

What could go right

  • Global pharma R&D outsourcing

What could go wrong

  • Biotech funding-cycle sensitivity

Moat: narrow (scale, customer qualification). Broad building-block catalog and qualified GMP capacity are costly to replicate.

Headquarters: Nanjing, China · Employees: 2,593

PharmaBlock Sciences (Nanjing) at a glance

Size PharmaBlock Sciences (Nanjing) (300725.SZ) is a China Industrials company (Miscellaneous Commercial Services) with a market value of $1.36B, the 1658th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥40.06 on 18 Nov 2026.

Performance Over six months the shares gained 5.4%, against -17.4% for the median peer and -20.0% for the China market (cap-weighted) — 7th highest of 21 in its peer set.

Growth Revenue grew 10.6% over the last twelve months (peer median +4.9%); the operating margin is 10.7% (peer median 7.6%).

Valuation It trades at 37.5× forward earnings against a peer median of 19.1× (6th most expensive of 18).

Price implies For today's price to make sense, revenue must grow about 24% a year for seven years (Req g). Recent delivered growth is +14%, so the hurdle is +10 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 3.6 points below its cost of capital (11.7% WACC).

Next results Next results expected around 28 Apr 2027 (exchange calendar; dates can move).

Relative performance

7510012515021 May 202621 Aug 202618 Nov 2026300725.SZ 108Peer median 82
Six months, rebased to 100: PharmaBlock Sciences (Nanjing) against the median of its 20 peers (local-currency closes).

PharmaBlock Sciences (Nanjing) financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥2.19BCN¥1.96BCN¥1.68BCN¥1.72BCN¥1.58B
Revenue growth—+17%-2%+9%—
Gross profitCN¥801MCN¥566MCN¥598MCN¥689MCN¥675M
EBITDAn/aCN¥332MCN¥357MCN¥381MCN¥375M
Net incomeCN¥222MCN¥184MCN¥220MCN¥197MCN¥314M
Free cash flowCN¥46.9MCN¥571MCN¥231M-CN¥41.1M-CN¥291M
Capital expenditureCN¥376MCN¥140MCN¥118MCN¥316MCN¥558M
Total debtCN¥95.6MCN¥181MCN¥1.46BCN¥1.83BCN¥1.71B

Quarterly statements and history in the cockpit →

PharmaBlock Sciences (Nanjing) competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%0%+20%CRAI2384DBG688128600654002338CLVTCMPDI688202301413002607ICFI9746688351AFRY603406600662MOL688800300725.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. PharmaBlock Sciences (Nanjing) is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%0×200×400×CRAI2384DBG688128002338CLVT688202301413002607ICFI9746688351600662MOL000681688800300725.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. PharmaBlock Sciences (Nanjing) is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%+60%-25%0%25%50%CRAI2384DBG688128600654CLVT002607ICFI9746688351000681688800300725.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. PharmaBlock Sciences (Nanjing) is the large dot.

PharmaBlock Sciences (Nanjing) competitors and peer comparison

How PharmaBlock Sciences (Nanjing) compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

PharmaBlock Sciences (Nanjing) against its 20 peers (data as of 18 Nov 2026)
Measure300725.SZPeer medianRank in peer set
1-month return-11.9%-0.5%5th lowest of 21
6-month return+5.4%-17.4%7th highest of 21
Distance from 52-week high-30.4%-37.8%8th highest of 21
Revenue growth (TTM)+10.6%+4.9%8th highest of 21
Operating margin10.7%7.6%6th highest of 21
Forward P/E37.5×19.1×6th most expensive of 18
Growth the price implies (Req g, 7 yrs)24.2%6.6%4th most demanding of 17
Growth delivered (Del g)+14.1%+9.4%6th highest of 17
Hurdle (Req g minus delivered)+10.2 pp-5.7 pp5th most demanding of 17
ROIC minus cost of capital-3.6 pp+0.6 pp7th lowest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
PharmaBlock Sciences (Nanjing) 300725.SZChina$1.36B+5%+11%11%37.5×24.2%+14.1%
CRA International CRAIUnited States$1.35B+46%+13%10%23.3×6.6%+8.1%
SBS 2384.TJapan$1.35B+26%+17%5%13.9×-4.7%+13.8%
Derichebourg DBG.PAFrance$1.37B-18%-3%5%8.8×6.7%+6.3%
China National Electric Apparatus Research Institute 688128.SSChina$1.35B-17%+8%11%14.7×3.2%+13.5%
China Security 600654.SSChina$1.34B-31%-30%-1%n/a56.0%+0.4%
Changchun Up Optotech 002338.SZChina$1.34B-41%+22%2%43.1×n/an/a
Clarivate CLVTUnited States$1.38B-12%-9%8%3.5×13.2%+14.4%
Central Mine Planning & Design Institute CMPDI.NSIndia$1.38B-22%+10%33%n/a4.5%+18.7%
Shanghai Medicilon 688202.SSChina$1.39B+8%+42%-2%85.1×n/an/a
Shenzhen Ampron Technology 301413.SZChina$1.40B-28%+11%2%387.2×n/an/a
Offcn Education Technology 002607.SZChina$1.40B-40%-2%13%34.7×15.7%-27.6%
ICF International ICFIUnited States$1.40B+14%-5%8%10.4×-2.5%+4.4%
TKC 9746.TJapan$1.31B+22%+5%20%19.1×-10.1%+5.7%
Shanghai MicroPort EP Medtech 688351.SSChina$1.31B-30%+20%3%137.1×42.5%+26.7%
AFRY AFRY.STSweden$1.42B+5%-4%7%12.5×-2.2%+6.3%
Yangzhou Tinfulong 603406.SSChina$1.42B-29%-4%12%n/a6.1%+10.6%
Shanghai Foreign Service 600662.SSChina$1.42B-14%+1%2%13.2×n/an/a
Moltiply MOL.MIItaly$1.45B+12%+20%16%14.0×10.9%+21.0%
Visual China 000681.SZChina$1.46B-34%-9%4%37.6×57.8%+6.5%
Suzhou Recodeal Interconnect System 688800.SSChina$1.26B-68%+5%9%31.0×22.7%+38.9%

Questions

Which companies are PharmaBlock Sciences (Nanjing)'s closest peers?
The cockpit's peer set: CRA International (CRAI), SBS (2384.T), Derichebourg (DBG.PA), China National Electric Apparatus Research Institute (688128.SS), China Security (600654.SS), Changchun Up Optotech (002338.SZ), Clarivate (CLVT), Central Mine Planning & Design Institute (CMPDI.NS).
Is PharmaBlock Sciences (Nanjing) expensive compared with its peers?
On forward p/e it trades at 37.5× against a peer median of 19.1×, 6th most expensive of 18 in its peer set. For today's price to make sense, revenue must grow about 24% a year for seven years (Req g). Recent delivered growth is +14%, so the hurdle is +10 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has PharmaBlock Sciences (Nanjing) stock performed?
Over six months to 18 Nov 2026 the shares returned +5.4% against -17.4% for the median peer; over one year -3.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.